GiveWell Commits at Least $2.5 Billion to Malaria for 2027–2032. There Is No Application Form, and Most of the Money Will Reach Countries Through the Global Fund.

On October 26, 2026, GiveWell published a post titled "Further Scaling Our Malaria Grantmaking." The headline number is that GiveWell aims to grant at least $2.5 billion in new malaria funding from 2027 through 2032, and says the total could be "several times that amount."

That makes GiveWell one of the biggest single sources of new malaria money anywhere in the world for the rest of the decade. It is not, however, a grant program in the usual sense. There is no RFP, no deadline and no application portal. Organizations that treat it like one will waste their time. Organizations and governments that understand how it actually moves money are well placed to get it.

The Numbers Behind the Pledge

GiveWell's growth explains the scale. The organization says it expects to grant more than $1 billion in 2026, more than double the $418 million it committed in 2025. Its research team has also more than doubled since the start of last year.

Malaria has been GiveWell's largest category for years. By its own count it has directed more than $1.3 billion to malaria so far, including more than $750 million for insecticide-treated nets and more than $500 million for seasonal malaria chemoprevention (SMC). GiveWell estimates that this funding will save more than 300,000 lives.

The new commitment sets a floor of roughly $420 million a year for six years. That is about what GiveWell gave across all of its causes in 2025.

Why Now: The Multilateral Money Shrank

GiveWell is explicit that this is a response to a funding gap, not a change in what it believes. Its post sets out the arithmetic:

• The Global Fund's latest replenishment raised $12.6 billion, down from $15.7 billion three years earlier and well short of its $18 billion target.
• The Global Fund allocated $3.5 billion to countries for the next three years of malaria grants, about 15% less than the previous cycle.
• Gavi raised just under $10 billion of its $11.9 billion budget for 2026–2030 and cut the malaria vaccine coverage it will fund.
• Newer tools cost more than the ones they replace. Dual-ingredient nets, which counter insecticide resistance, are more expensive than standard pyrethroid nets.

Add the collapse of U.S. bilateral health aid after USAID was dismantled in 2025 and the picture is plain. The main institutional funders of malaria control have all shrunk at once, and malaria still kills about 600,000 people a year, most of them young children. GiveWell's bet is that marginal malaria dollars are now worth more than they have been in a decade.

What GiveWell Will Fund

The post lists program areas under consideration and says the list is "neither comprehensive nor final":

• Prevention: insecticide-treated nets, SMC and malaria vaccines, including more frequent campaigns or wider age and geographic coverage.
• Testing and treatment: case management by community health workers, plus supply-chain support.
• Newer tools: spatial emanators and insecticide-treated babywraps, if the evidence is strong enough. GiveWell says it may fund some of the trials itself.

GiveWell is candid about where its confidence lies. It is most confident in net campaigns and SMC for young children. It says it is still developing its view on community health workers, supply chains, chemoprevention for older children, and scaling vaccines and newer tools.

For implementers, this ranking matters more than the list. A net-distribution or SMC organization with good coverage data competes in a category GiveWell already understands and funds at scale. An organization offering community case management or a new vector-control product is asking GiveWell to build a cost-effectiveness model it does not yet have. That route is slower, and in the near term it is more likely to start with a pilot, a trial or a data-collection grant than with a large program award.

The 6x Bar Is the Real Eligibility Criterion

GiveWell currently funds programs it estimates are at least 6 times as cost-effective as its benchmark (unconditional cash transfers). The post says the bar could fall if more funding becomes available, and that it may change over time.

This is the only eligibility rule that matters. Organization type, country and size do not determine whether a malaria program gets GiveWell money. What determines it is whether GiveWell's model, using the burden, coverage and cost figures for a specific place, says the program clears 6x.

Two practical consequences follow:

1. Geography is destiny. Cost-effectiveness depends heavily on malaria burden. The same net campaign can clear the bar in a high-transmission Sahelian district and fall short in a lower-burden area. GiveWell has said it will focus on fewer, higher-burden countries.
2. Unit cost data is your proposal. GiveWell's models depend on cost per person reached, coverage achieved and baseline prevalence. An implementer that can document those figures, and has independent coverage surveys to back them up, is giving GiveWell exactly what it needs. Narrative impact claims do not help.

The Malaria Impact Accelerator

The most consequential part of the announcement is the proposed Malaria Impact Accelerator, a partnership with the Global Fund. It has three components:

1. Country "investment requests", submitted through the Global Fund's existing Country Coordinating Mechanisms (CCMs).
2. A "fast track" for urgent gaps, such as a net campaign about to stall for lack of funds.
3. Complementary work on new tools, affordability and evidence generation.

It would differ from standard Global Fund grantmaking in several ways. The money would be malaria-specific. Allocations would track malaria burden more closely. It would reach fewer, higher-burden countries. It would fund only programs above GiveWell's bar. And independent monitoring results would be published.

Review would be split. The Global Fund's Technical Review Panel would assess technical soundness, and GiveWell would assess cost-effectiveness.

Two caveats are central. First, the Global Fund's board has not approved the mechanism, and the Fund is about to select a new executive director. Second, GiveWell lists the risks itself: weak commitment or capacity at the Global Fund, poor coverage in past Global Fund programs, less country interest than expected, and the chance that its money crowds out government or donor spending. If the Accelerator produces less than expected, GiveWell says it will scale through other grantees instead.

What this means for ministries and CCMs: if the Accelerator is approved, national malaria programs in high-burden countries get a new, malaria-only window with its own allocation. Programs should prepare now. That means current coverage survey data, costed gap analyses for nets and SMC, and a clear account of which districts lost Global Fund or U.S. support. GiveWell says it will publish country allocations and guidance once the board approves the mechanism.

Grant Structure: Shorter Grants, Pre-Committed Renewals

GiveWell says it is working to secure resources for five to six years, but initial grants will cover about two to three years, with renewal funding set aside in advance. Renewal depends on government interest, coverage survey results, prevalence trends, and whether other malaria funding has fallen further.

GiveWell also commits to responsible exits. If funding is reduced, it plans gradual step-downs, advance notice and exit funding. Recent experience gives that promise weight. Implementers whose USAID or President's Malaria Initiative funding ended abruptly in 2025 know that the end of a grant can do as much damage as never getting one.

The Data Requirements Are Heavy

GiveWell will spend real money on evidence. Its plans include:

• Nationally representative household surveys before major funding decisions, with approval from national programs.
• Stronger routine health-facility data.
• Monitoring of drug and insecticide resistance, and of mosquito populations.
• Independent household coverage surveys and verification visits to people reported as reached.
• Impact estimation by comparing areas with different funding levels and using program age cutoffs to compare similar groups.

This creates a second opportunity alongside implementation funding: research and survey firms, entomology labs and data-systems organizations with a track record in malaria monitoring. GiveWell lists "fund baseline data collection" as a near-term step, so this work comes before the large implementation grants.

Who Should Act, and How

Established GiveWell grantees such as the Against Malaria Foundation and Malaria Consortium are the most direct channel. GiveWell names both and says immediate gaps, including net campaigns, may be funded through them. Smaller implementers may find that partnering with or subcontracting to these organizations is the fastest way in.

Other implementers with net, SMC or case-management programs should contact GiveWell's research team with cost and coverage data rather than wait for an RFP that will not come. GiveWell has long said it considers organizations proactively, but it decides what to fund based on its own models. Lead with unit costs, coverage surveys and the specific funding gap in a specific geography.

National malaria control programs and CCMs should watch the Global Fund board's decision on the Accelerator. If it passes, the country investment request becomes the main channel and will reward countries that have current data ready.

Vaccine and new-tool developers should note the separate Gavi track. GiveWell says it is exploring funding malaria vaccines through Gavi to reach more people. For product developers earlier in the pipeline, GiveWell's willingness to fund trials of spatial emanators and treated babywraps is a rare philanthropic offer to pay for the field evidence that decides adoption. U.S. federal money for next-generation vaccine research is also open: see our analysis of NIAID's RFA-AI-28-024 malaria vaccine program.

The Larger Shift

This announcement fits a pattern that has accelerated through 2026. Philanthropies that applied cost-effectiveness rules to small slices of global health are now taking on budgets that bilateral donors used to carry. In the same week, Coefficient Giving (formerly Open Philanthropy) said it would donate equity from its for-profit AI and biosecurity investments to the Against Malaria Foundation by default.

The shift moves money away from implementers with good relationships toward those with good data. GiveWell says outright that it will publish its monitoring results, so performance will be visible. The groups best placed to grow with this $2.5 billion are those that can show, district by district, what a dollar bought.

Granted tracks foundation commitments like this alongside federal and multilateral programs. For an organization working in global health, that puts a GiveWell funding channel in the same view as the NIH or USAID-successor programs it might braid with.